Form 4: Exelixis EVP Haley Receives RSU Grant

Exelixis, Inc. EVP, Commercial Patrick J. Haley was granted 40,459 restricted stock units, vesting over several years.

Summary

• Patrick J. Haley, Executive Vice President, Commercial of Exelixis, Inc. (EXEL), was granted 40,459 shares of common stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this grant was February 26, 2026.
• These RSUs were granted at a price of $0 per share, indicating they are part of an equity incentive plan.
• The RSUs will vest in installments: 1/4th on May 15, 2027, and 1/4th on each subsequent May 15th until fully vested.
• Following this transaction, Patrick J. Haley beneficially owns 422,367 shares of common stock, which includes the newly granted RSUs and previously awarded RSUs and performance-based restricted stock units (One-Time Award PSUs) granted on March 31, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The grant of Restricted Stock Units aligns the executive's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• Equity grants are a standard component of executive compensation, indicating a structured approach to retaining key talent.

Negatives

• The vesting of these RSUs will result in a minor dilution of existing shareholder equity over time as new shares are issued.

Risks

• The value of the RSU grant is dependent on the future stock price of Exelixis, Inc., which is subject to market fluctuations and company performance.

Future Outlook

The granted Restricted Stock Units are scheduled to vest in four annual installments, with the first vesting on May 15, 2027, and subsequent vestings on May 15th of each following year until fully vested.

Industry Context

StockSavvy.ai notes that RSU grants are a common and widely accepted form of long-term incentive compensation for executives in the biotechnology and pharmaceutical sectors, aiming to align management's long-term interests with shareholder value creation. This filing reflects a routine compensation event within the industry.

Comparison to Industry Standards

• Equity incentive plans, such as the Exelixis, Inc. 2017 Equity Incentive Plan, are standard practice across publicly traded companies, particularly in high-growth sectors like biotech, to attract and retain executive talent.
• The vesting schedule of 1/4th annually over four years is a typical structure for RSU grants, comparable to practices at peer companies like Amgen or Gilead Sciences, designed to encourage long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The grant of 40,459 Restricted Stock Units to Patrick J. Haley, an Executive Vice President of Exelixis, Inc., constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon RSU vesting, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: This specific filing pertains to executive compensation and does not directly impact the broader employee base, though it reflects the company's overall compensation philosophy.

Next Steps

• Vesting of 1/4th of the granted RSUs on May 15, 2027.
• Subsequent annual vesting of 1/4th of the granted RSUs on May 15th of each year until fully vested.

Key Dates

Keywords

Exelixis, EXEL, Restricted Stock Units, RSU grant, insider transaction, executive compensation, equity incentive plan, Form 4